2 results
Approved WMOCompleted
To demonstrate the additive IOP lowering effect of SIMBRINZA (dosed BID) when added to DUOTRAV solution in subjects with open-angle glaucoma or ocular hypertension.
Approved WMOCompleted
The main objective of the current proof-of-concept study is to explore the feasibility, acceptance and potential (clinical) added value of Sense-IT in a sample of psychiatric patients with ASD/ID/BPD and their psychiatric nurses.